Ani Pharmaceuticals, Inc
Could not find a ticker for this position, may be a filing error
A maker of specialty drugs for rare diseases and generics, based in Baudette, Minnesota, that makes medicines like Purified Cortrophin Gel, an injected therapy for conditions including multiple sclerosis and rheumatoid arthritis. The company grew out of a 2013 merger with BioSante Pharmaceuticals, and its origins trace to an earlier Cortrophin Gel first approved in the 1950s but discontinued decades later. ANI brought that long-vanished drug back to U.S. shelves after buying its rights, and no one has ever explained what the initials "ANI" actually stand for.
3% convertible bond due December 1, 2019
Granted 16.92M
Granted 16.92M
Sold 1.00M
Bought 50.0K
Granted 1.43M · Bought 10.0K · Sold 900.7K
Granted 4.86M · Sold 458.5K
Granted 861.4K · Bought 7.2K · Sold 281.0K
Granted 11.1K · Sold 268.6K
Granted 469.6K · Bought 10.0K · Sold 234.7K
Granted 100.6K · Bought 25.0K
Granted 576.6K · Bought 3.5K · Sold 234.1K
Granted 363.0K · Sold 101.4K
Granted 630.8K · Sold 87.8K
Granted 165.0K · Sold 42.2K
Granted 156.4K · Sold 55.4K
Granted 86.8K
Granted 145.2K · Sold 35.5K
Granted 106.3K · Sold 11.3K
Granted 138.8K · Sold 45.0K
Granted 89.4K · Sold 22.3K
Granted 49.0K
Granted 414.5K
Bought 20.0K
Granted 52.2K · Bought 9.0K
Granted 50.2K · Bought 10.0K · Sold 21.3K
Granted 37.1K · Bought 1.4K
Granted 55.0K · Bought 24.0K · Sold 37.6K
Granted 19.1K · Sold 10.2K
Bought 15.0K
Granted 33.3K · Sold 3.8K
Granted 46.7K · Bought 2.6K · Sold 21.5K
Granted 46.7K · Bought 3.0K · Sold 22.7K
Granted 8.3K · Bought 457.6K
Bought 3.0K
Granted 13.1K · Sold 7.5K
Granted 14.3K
Granted 20.7K · Sold 9.5K
Granted 6.7K
Granted 5.6K
Granted 2.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Brown Robert E. JR +1 co-filerDirector, 10% owner · 1 transaction | — | 16.92Mas of Jun 2013 | 16.92M | — | — |
| Meridian Venture Partners II LP +2 co-filers10% owner · 1 transaction | — | 16.92Mas of Jun 2013 | 16.92M | — | — |
| Brown Robert E. JR +3 co-filers10% owner · 23 transactions | — | 1.82Mas of Aug 2023 | — | — | 1.00M |
| Morgenstern Victor ADirector · 3 transactions | — | 1.80Mas of Jan 2007 | — | 50.0K | — |
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS, Director · 74 transactions | — | 635.6K | 1.43M | 10.0K | 900.7K |
| Marshbanks TracyDirector · 36 transactions | — | 349.9Kas of May 2018 | 4.86M | — | 458.5K |
| Lalwani NikhilPRESIDENT & CEO, Director · 44 transactions | — | 344.5K | 861.4K | 7.2K | 281.0K |
| Raynor DanielDirector · 14 transactions | — | 300.1Kas of Mar 2018 | 11.1K | — | 268.6K |
| Gassert ChadSVP - CORP. DEV. & STRATEGY · 28 transactions | — | 233.4K | 469.6K | 10.0K | 234.7K |
| Simes Stephen MVice Chairman, President & CEO, Director · 6 transactions | — | 202.3Kas of Jan 2012 | 100.6K | 25.0K | — |
| PRZYBYL ArthurPresident and CEO, Director · 110 transactions | — | 190.3Kas of Apr 2020 | 576.6K | 3.5K | 234.1K |
| Carey Stephen P.SVP & CFO · 58 transactions | — | 177.5K | 363.0K | — | 101.4K |
| Marken James G.SVP OPS & PROD DEV · 64 transactions | — | 117.8Kas of Jun 2024 | 630.8K | — | 87.8K |
| Mutz ChristopherHEAD OF RARE DISEASE · 37 transactions | — | 91.3K | 165.0K | — | 42.2K |
| Schrepfer Robert WSVP - NEW BUS DEV & SPEC SALES · 41 transactions | — | 87.5Kas of Mar 2021 | 156.4K | — | 55.4K |
| Sherwin Stephen ADirector · 1 transaction | — | 86.8Kas of Mar 2012 | 86.8K | — | — |
| Gutwerg OriSVP, GENERICS · 37 transactions | — | 78.7K | 145.2K | — | 35.5K |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · 50 transactions | — | 77.9K | 106.3K | — | 11.3K |
| Arnold Charlotte C.Vice President and CFO · 65 transactions | — | 54.3Kas of Apr 2016 | 138.8K | — | 45.0K |
| Davis KristaSVP, CHIEF HR OFFICER · 30 transactions | — | 51.9K | 89.4K | — | 22.3K |
| Brown Robert E. JRDirector · 13 transactions | — | 49.0Kas of Apr 2022 | 49.0K | — | — |
| Jamnick Robert J.VP, Quality & Product Develop. · 3 transactions | — | 48.1Kas of May 2014 | 414.5K | — | — |
| Sullivan Louis WDirector · 2 transactions | — | 47.9Kas of Mar 2012 | — | 20.0K | — |
| Donenberg Philip BSr. VP of Finance, CFO & Secy · 12 transactions | — | 44.3Kas of Jan 2012 | 52.2K | 9.0K | — |
| Haughey ThomasDirector · 15 transactions | — | 38.9K | 50.2K | 10.0K | 21.3K |
| Nash DavidDirector · 7 transactions | — | 38.6Kas of May 2023 | 37.1K | 1.4K | — |
| Walsh Patrick DDirector · 21 transactions | — | 38.4K | 55.0K | 24.0K | 37.6K |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS · 13 transactions | — | 38.3K | 19.1K | — | 10.2K |
| Kjaer PeterDirector · 5 transactions | — | 34.4Kas of Apr 2010 | — | 15.0K | — |
| Tannenbaum Renee PDirector · 7 transactions | — | 29.5K | 33.3K | — | 3.8K |
| Thoma JeanneDirector · 11 transactions | — | 27.8K | 46.7K | 2.6K | 21.5K |
| Pera Antonio RDirector · 12 transactions | — | 27.0K | 46.7K | 3.0K | 22.7K |
| Mangano Ross JDirector · 18 transactions | — | 26.9Kas of Sep 2014 | 8.3K | 457.6K | — |
| Rosenow Edward C IIIDirector · 1 transaction | — | 20.5Kas of Mar 2012 | — | 3.0K | — |
| Holubow FredDirector · 13 transactions | — | 14.8Kas of Mar 2018 | 13.1K | — | 7.5K |
| Penn Thomas A.Director · 6 transactions | — | 14.3Kas of Mar 2019 | 14.3K | — | — |
| Leonard Matthew JDirector · 6 transactions | — | 11.2K | 20.7K | — | 9.5K |
| Gosebruch Henry ODirector · 1 transaction | — | 6.7K | 6.7K | — | — |
| Potts John T JrDirector · 1 transaction | — | 5.6Kas of Mar 2012 | 5.6K | — | — |
| Lankau Peter ADirector · 2 transactions | — | 2.5Kas of Apr 2016 | 2.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.26M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.